Big Pharma Faait Saari Duniya Ki Najar Bhaarat Par Tiki

India »

Big Pharma Faait Saari Duniya Ki Najar Bhaarat Par Tiki

big pharma faait saari duniya ki najar Bhaarat par tiki hai. Yah ek mahaayuddh hai, jismein ek taraf hai big pharma, yaani malteenaishanal dava companiyaan aur doosari taraf Bhaarat jaise vikaasasheel deshon ki pharma companiyaan. Yahaan hajaaron karod dollar ka baajaar daanv par laga hai. Yah ek aisi jang hai, jismein donon senaaen pablik ki bhalaai ki duhaai day rahi hain. Novaartis case mein Bhaarat ke Supreme court ke faisale ke baad ek mukaabala khatm ho raha hai. Yah tay ho gaya hai ki Bhaarat mein kya peteint ho sakta hai aur kya naheen. Lekin yah jang nae morchon par jaari rahegi. Aise hui shuruaat: Iski shuruaat tab hui, jab deshon ke beech trade ki global treeti ke saath peteint ka nijaam bhi badal gaya. Peteint ke tahat koi shakhs (ya company) apni khoj (intalekchual prauparti) ke karmashal raaits haasil karta hai, kyonki jisne nai khoj ki hai, use hi usase paisa kamaana chaahiye. Yah peteint 20 saal ke liye hota hai. Bhaarat mein tab tak davaaon ke maamale mein praudakt peteint chalta tha, yaani koi company apni khoji hui dava ko jis naam se bechati thi, us naam ka istemaal koi doosra naheen kar sakta tha. Lekin koi bhi us dava ki apne tareeke se nakal kar sakta tha. Tab jaise hi koi nai dava aati thi, usaki anginat sasti nakalein baajaar mein aa jaati theen, jinhein jenarik drags kaha jaata hai. Trade rileted aaspekts of intalekchual prauparti (trips) ke tahat yah system badal gaya. Global kaayade ke tahat proses peteint par bhi rok lag gayi. Yah nijaam 2005 mein kaanooni taur par laagoo huaa, jiske baad se kisi bhi peteinted dava ki nakal naheen ki ja sakti. Nakal ki ijaajat sirf tabhi hai jab peteint ki miyaad khatm ho jaae. Lekin naya system laagoo karte hue Bhaarat aur doosare vikaasasheel deshon ko yah chhoot mili ki agar peteint dava aam logon ki pahunch se door ya mahangi hai ya koi imarajeinsi hai, to sarkaar doosari companiyon ko nakal ki ijaajat day sakti hain, jise kanpalasari laaiseinsing kaha gaya. Iske alaava, Bhaarat mein jo kaanoon bana, usamein bhi peteint tay karne ke kuchh nukte the, jo baad mein vivaad ki vajah bane. Masalan peteint kaanoon ka sekshan 3dee. Novaartis ka yah maamala isi doosari vajah se shuroo huaa, jahaan Bhaarat ne usaki dava ko nai khoj maanane se inkaar kar diya. Pablik ke naam par takkar global pharma companiyon ka kehna hai ki nai dava khojane mein bhaari kharch aata hai. Agar dava ki keemat se iski bharpaai naheen hogi, to koi company nai davaaen kyon khojegi? Tab beemaariyon se ham kaise ladeinge? Yah tarakki ko rokana hoga. Udhar , jenarik companiyon ka kehna hai ki big pharma bhaari munaafaakhori mein laga hai. Davaaon ke daam itne oonche rakhe jaate hain ki pablik ya to lutati hai ya bina ilaaj ke rah jaati hai. 70,000 karod rupaye ka hai bhaarateeya dava baajaar 90 parseint hissa ismein jenarik davaaon ka. Kissa glivek ka yaani kya hai peteint ke laayak Swiss dava company novaartis 1998 se Cancer ki dava glivek ka Bhaarat mein peteint haasil karne ki koshish karti rahi hai. Yah kraunik maayalauid lyookemiya ki dava hai. Ise sekshan 3( di ) ke tahat peteint ke kaabil naheen maana gaya. Kya hai 3( di ) : Kisi jaane - pahachaane tatv ( sabastains ) ke nae roop ko peteint naheen kiya ja sakta. Peteint ke liye jaroori hai ki us tatv mein naya asar khoja jaae. Yaani Bhaarat mein yah mumkin naheen ki thode bahut sudhaar ko inoveshan maanate hue peteint day diya jaae. Novaartis ne is faisale ko chaileinj kiya. Usane kaha , hamaara sudhaar inkreemeintal inoveshan hai , yaani yah dava ko behtar banaata hai. Aisa inoveshan dava ka asar badha sakta hai , side ifekt ghata sakta hai aur mareej ke liye use aasaan bana sakta hai. Novaartis ki doosari maang yah thi ki sekshan 3( di ) ko hataaya jaae , kyonki yah trips ke khilaaf jaata hai. Lekin virodhiyon ne kaha ki yah evaragereening ki chaal hai , yaani puraani dava ko herafer ke baad nai bataakar peteint jaari rakhana. 1.2 lakh rupaye maahavaar hai glivek ki khuraak ki keemat 8 se 10 hajaar rupaye mein maujood hai iska jenarik varjan 5 arab dollar hai glivek ka global market timeline 1998- glivek ke liye peteint aavedan 2001- maarketing ki ijaajat 2005- Indian peteint ameindameint act bana 2006- peteint office ne arji radd ki. 2009- peteint apeelet board se bhi khaarij 2011- maamala Supreme court mein 2012 (11 September )- sunavaai shuroo hui jo 4 December 2012 ko poori 2013 (1 April )- Supreme court ka faisala novaartis ke khilaaf gaya pichhle saal ye davaaen bhi peteint naheen pa sakeen : - faaijar ki Cancer dava sutent - Ross ki haipetaaitas - si dava pegaasis - mark ki asthama ki dava . . Aur yah doosra morcha kissa naiksaavar ka , yaani kya ho dava ki keemat pichhle saal 9 March ko sarkaar ne naitako pharma ko baayar ki keemotherepi dava naiksaavar ( kidni - leevar ke Cancer ke liye ) ka jenarik banaane ki ijaajat dete hue kanpalasari license jaari kar diya. Daleel yah thi ki baayar ki dava kifaayati daam par logon ko naheen mil rahi , jo ki pablik helth ke liye bura hai. Badle mein naitako ko 6 parseint rauyalti baayar ko deni thi. Baayar ne apeelet board mein appeal ki. Pichhle maheene board ki Chairman Justice prabha shreedevan ne baayar ki appeal radd kar di. Sirf rauyalti badhaakar 7 parseint kar di gayi. Yah pehli baar hai jab kanpalasari laaiseinsing ko maanyata mili hai. -2,80,000 rupaye maahavaar hai baayar ki dava ki keemat -8,800 rupaye ki padti hai naitako ki dava silsila beedeeaar pharma ne Bristol maayars ki blood Cancer dava desitiniv ki nakal ke liye kanpalasari license ka daava kiya hai. Beedeeaar ka kehna hai ki vah 8,100 rupaye mein yah dava bechegi , jabki Bristol ki dava ki maasik doj 1.65 lakh ki padti hai. - ikvaador , Brazil , Indonesia aur Thailand mein bhi kanpalasari license jaari kiye ja rahe hain. - Bhaarat mein ek sarkaari committee ne prati vyakti aamdani ke hisaab se davaaon ki keemat rakhane ki sifaarish k i hai.

Big Pharma Faait Saari Duniya Ki Najar Bhaarat Par Tiki https://www.angrejinews.com/pic/4157